Oral Sabizabulin for High-Risk Adults with Covid-19Barnette et al. report on an interim analysis of a phase 3 randomized controlled trial of the orally available novel microtubule disruptor sabizabulin for severe Covid-19. They find a reduction in 60-day mortality from 45.1% to 20.2%.